

**MENJONG SORIG PHARMACEUTICALS CORPORATION LTD.**  
**THIMPHU, BHUTAN**

**STATEMENT OF COMPREHENSIVE INCOME**  
for the Quarter ended 30th June, 2021

PARTICULARS	Note No.	QUARTER ENDED	QUARTER ENDED
		30-06-2021	30-06-2020
		(Nu.)	(Nu.)
<b><u>REVENUE</u></b>			
Sales	14	33,488,926.21	41,443,937.53
Other Income	15	444,225.00	317,418.00
<b>Total Revenue</b>		<b>33,933,151.21</b>	<b>41,761,355.53</b>
<b><u>EXPENDITURE</u></b>			
Changes in Finished Goods & Work-in-Progress	16	(428,485.08)	11,272,641.46
Raw Materials & Packaging Materials Consumed	17	13,143,314.29	13,470,633.50
Manufacturing Expenses	18	1,782,870.25	1,577,270.98
Employee Benefit Expenses	19	12,004,813.00	12,916,609.00
Finance Cost	20	3,847.38	420.00
Depreciation & Amortization	01	4,534,305.36	4,253,929.02
Other Expenses	21	1,426,074.40	1,978,782.40
<b>Total Expenditure</b>		<b>32,466,739.59</b>	<b>45,470,286.36</b>
<b>Profit/(Loss) before Tax</b>		1,466,411.62	(3,708,930.83)
<b><u>Tax Expense</u></b>			
Current Tax		-	-
<b>Net Profit/(Loss) for the Year</b>		<b>1,466,411.62</b>	<b>(3,708,930.83)</b>
<b>Other comprehensive income</b>			
<i>Items that will not be reclassified to profit or loss</i>			
Remeasurements of post-employment benefit obligations		-	-
Income tax relating to above item		-	-
<b>Other comprehensive income, net of tax</b>		-	-
<b>Total comprehensive income</b>		<b>1,466,411.62</b>	<b>(3,708,930.83)</b>
<b>Earnings per equity share</b>			
Basic and diluted			
Notes on Financial Statements forms integral part of Accounts	22	0.80	(2.03)

This is the Statement of Comprehensive Income referred to in our report of even date.

**For Burman Singh & Associates**  
**Chartered Accountants**  
**FRN No: 326113E**

**Chairman**

**Chief Executive Officer**

**Ram Nath Singh**  
**(Partner)**  
**Mem.No-063418**

**Director**

Place : THIMPHU

Date : , 2021